Jun 2021 – Present · 4 yrs 11 mos

• Executive Leader of a department making molecules into medicines, by driving target ID and assessment, ADME, safety/toxicology, non-clinical pathology, DMPK, regulated bioanalysis and biosample operations, clinical pharmacology and pharmacometrics, PK/PD modeling and simulation, and biomarker development and implementation, from early discovery through clinical stages of development.
• Our teams support >130 molecule programs end-to-end including Ph3, global filing and post-approval commitments in the areas of neuroscience, neuromuscular diseases, ophthalmology, oncology, cardiovascular, metabolic disease and obesity, autoimmune and infectious diseases.
• Co-chair of Early Strategic Portfolio Committee (ESPC).
• Publications on Google Scholar:
• https://scholar.google.com/citations?user=2-_3RGsAAAAJ&hl=en&oi=ao

Mar 2020 – Mar 2021 · 1 yr

• Heading the Early Development group of Medical Directors, Clinical Scientists and Patient Partnership Directors in Neuroscience and Rare Diseases. Department responsible for clinical development of neuroscience and rare disease assets from clinical candidate selection through Phase 2, and alignment with early Research and Late Stage development programs. Assessment of clinical development plans for early portfolio assets and external assets. Development Review Committee Chair.

May 2018 – Jun 2021 · 3 yrs 1 mo

• Executive leader of a multidisciplinary biomarker team focused on Neuroscience and Rare Diseases.
• Developing sophisticated technical expertise and capabilities to measure key pharmacodynamic responses, target engagement, and proof-of-mechanism for therapeutics in the early and late development portfolios.
• Defining strategies to implement biomarkers in clinical development using a broad scope of approaches including MRI and PET imaging; electrophysiology; digital biomarkers measuring motor functions and behavioral responses; and biochemical markers in body fluids.
• Evidence generation, collaborating with global consortia, and health authority interactions. Utilizing biomarker insights to develop personalized health care (PHC) strategies for our candidate medicines.

Mar 2016 – May 2018 · 2 yrs 2 mos

• Senior Leader of an interdisciplinary division within Pharmaceutical Sciences at Roche; Head of Translational Biomarker Leaders for programs in autoimmune and infectious diseases.
• Development of strategies to define and measure therapeutic mechanism of action, target identification, target engagement, pharmacodynamic responses, and biomarkers. Focus on discovery and clinical development across multiple therapeutic areas including oncology, inflammation and infectious diseases, neuroscience, ophthalmology, and rare diseases.
• Groups include: Discovery Proteomics focusing on expression proteomics, chemoproteomics, post-translational modifications, and metabolomics; assessment of cellular responses by multicolor Flow Cytometry in clinical samples; and protein biomarker discovery and clinical analysis utilizing cutting-edge Clinical Immunoassay techniques.

Nov 2014 – Mar 2016 · 1 yr 4 mos

• Developing strategies for clinical biomarker development using immunoassays and metabolomics platforms.
• Experimental and clinical immunoassays for protein biomarkers across a wide variety of disease therapeutic areas, and creating new assays using a wide range of ultrasensitive, singleplex and multiplex platforms.
• Expanding understanding of disease mechanism and biomarker discovery, using targeted and untargeted mass-spectrometry based metabolomics technologies. Metabolic pathway mapping, hypothesis development, and biomarker identification.

Jan 2009 – Jan 2014 · 5 yrs · La Jolla, CA

• Professor in the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences.
• Academic laboratory interested in contemporary therapeutic strategies for generating new and more efficient nanotechnology-based imaging agents, cancer therapeutics and antimicrobials.
• Development of in vivo models for infectious and inflammatory diseases and tumor therapeutics employing a array of structural, molecular, chemical, and mass spectrometry-based approaches to define targeting strategies and disease signatures. Supported by the National Institutes of Health, the American Heart Association, and Industry partnerships.
• Training: postdoctoral fellows, Pharm D. and Ph.D. students in the laboratory. Lead professor for Clinical Pharmacokinetics in the Pharm.D. and M.D. programs. Chair of admissions for MD/PhD program (MSTP) in the UCSD Health Sciences

Jan 2003 – Jan 2009 · 6 yrs · La Jolla, CA USA

• Tenured faculty member in the Cell Biology department. Development of targeted nanoparticle-based therapeutics for cancer and infectious disease. Leader of multi-center consortium in targeted oncology therapeutics. Head of a multi-center program for development of novel antitoxins and leader of DMPK/PD testing core.

Jan 1998 – Jan 2003 · 5 yrs · La Jolla, CA USA

• Departments of Neuropharmacology and Cell Biology. Understanding virus-host interactions, immunopathogenesis of CNS infections in transgenic animal models. Development of novel nanotherapeutics for virus infections.